miRNAs emerge as circulating biomarkers of post-myocardial infarction heart failure

Cruz, Marina Sampaio; Silva, Ananília Medeiros Gomes da; Souza, Karla Simone Costa de; Luchessi, André Ducati; Silbiger, Vivian Nogueira

doi:10.1007/s10741-019-09821-1

Cited by 19 publications

(14 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, microRNAs (miRNAs), a group of small noncoding RNAs, were biologically crucial to the modulation of downstream targets. On the contrary, previous studies showed that miRNAs could also exert protective or facilitating effects in the development of MI relying on a variety of ways (Cruz et al, 2019). For instance, miR‐488‐3p suppresses the acute cardiomyocyte apoptosis induced by MI via targeting ZNF791 (Zheng et al, 2019).…”

Section: Introductionmentioning

confidence: 91%

Knockdown of HIF1A‐AS2 suppresses TRIM44 to protect cardiomyocytes against hypoxia‐induced injury

Luo

Zhu

et al. 2020

Cell Biology International

View full text Add to dashboard Cite

Myocardial infarction (MI) is a common cardiovascular disease characterized by an interruption of blood and oxygen supply to the heart, which results in gradual damage to the myocardial tissue and ultimately heart failure. The role of long non‐coding RNAs in the pathology of MI remains in its infancy, but has been implicated in MI and other heart conditions. For example, the expression of a non‐coding RNA hypoxia‐inducible factor 1α (HIF1A)‐antisense RNA 2 (HIF1A‐AS2) has previously been linked to coronary heart disease, however, whether HIF1A‐AS2 expression is also high in MI has not been addressed. Here, we report that HIF1A‐AS2 is upregulated in hypoxia‐treated human cardiomyocytes (HMCs) compared with normal cardiomyocytes, and that silenced HIF1A‐AS2 inhibited apoptosis and facilitated viability, migration, and invasion of HMCs. Our data suggested that in MI, HIF1A‐AS2 upregulation was associated with miR‐623, which promoted expression of tripartite motif containing 44 (TRIM44). Moreover, by upregulating TRIM44 we were able to remedy the HIF1A‐AS2 repression of apoptosis in HMCs. Thus, we conclude that cardiomyocytes can be protected against hypoxic‐treated injury by knockdown of HIF1A‐AS2, which suppresses TRIM44, and that HIF1A‐AS2 overexpression is a prognostic indicator of MI.

show abstract

Section: Introductionmentioning

confidence: 91%

Knockdown of HIF1A‐AS2 suppresses TRIM44 to protect cardiomyocytes against hypoxia‐induced injury

Luo

Zhu

et al. 2020

Cell Biology International

View full text Add to dashboard Cite

show abstract

“…It is known that myocardial infarction and ischaemic heart disease are the major determinants for the development of HF [188,189]. Furthermore, where HF is of a nonischaemic origin, in cases of structural and "functional" cardiomyopathies, the lack of myocardium is the primary issue to be addressed for a robust cardiomyocyte replacement [190,191]. Regenerative medicine aims to find a therapy that is both effective and broadly available to refresh the contractile muscle cells lost and/or rendered permanently dysfunctional as a consequence of the primary injury [190,191].…”

Section: Impairment and Senescence Of Cardiac Stem Cells In Hfmentioning

confidence: 99%

“…Furthermore, where HF is of a nonischaemic origin, in cases of structural and "functional" cardiomyopathies, the lack of myocardium is the primary issue to be addressed for a robust cardiomyocyte replacement [190,191]. Regenerative medicine aims to find a therapy that is both effective and broadly available to refresh the contractile muscle cells lost and/or rendered permanently dysfunctional as a consequence of the primary injury [190,191]. Unfortunately, the predominant scepticism about the intrinsic endogenous regenerative capacity of the adult mammalian heart, including the human heart, has produced often contradictory approaches in myocardial repair/regeneration [191].…”

Section: Impairment and Senescence Of Cardiac Stem Cells In Hfmentioning

confidence: 99%

“…Regenerative medicine aims to find a therapy that is both effective and broadly available to refresh the contractile muscle cells lost and/or rendered permanently dysfunctional as a consequence of the primary injury [190,191]. Unfortunately, the predominant scepticism about the intrinsic endogenous regenerative capacity of the adult mammalian heart, including the human heart, has produced often contradictory approaches in myocardial repair/regeneration [191]. This skepticism can only be overcome if hard, clean and clear scientific data are obtained, thereby eliminating the need for interpretations and opinions.…”

Section: Impairment and Senescence Of Cardiac Stem Cells In Hfmentioning

confidence: 99%

See 1 more Smart Citation

Pathophysiological Basis for Nutraceutical Supplementation in Heart Failure: A Comprehensive Review

et al. 2021

View full text Add to dashboard Cite

There is evidence demonstrating that heart failure (HF) occurs in 1–2% of the global population and is often accompanied by comorbidities which contribute to increasing the prevalence of the disease, the rate of hospitalization and the mortality. Although recent advances in both pharmacological and non-pharmacological approaches have led to a significant improvement in clinical outcomes in patients affected by HF, residual unmet needs remain, mostly related to the occurrence of poorly defined strategies in the early stages of myocardial dysfunction. Nutritional support in patients developing HF and nutraceutical supplementation have recently been shown to possibly contribute to protection of the failing myocardium, although their place in the treatment of HF requires further assessment, in order to find better therapeutic solutions. In this context, the Optimal Nutraceutical Supplementation in Heart Failure (ONUS-HF) working group aimed to assess the optimal nutraceutical approach to HF in the early phases of the disease, in order to counteract selected pathways that are imbalanced in the failing myocardium. In particular, we reviewed several of the most relevant pathophysiological and molecular changes occurring during the early stages of myocardial dysfunction. These include mitochondrial and sarcoplasmic reticulum stress, insufficient nitric oxide (NO) release, impaired cardiac stem cell mobilization and an imbalanced regulation of metalloproteinases. Moreover, we reviewed the potential of the nutraceutical supplementation of several natural products, such as coenzyme Q10 (CoQ10), a grape seed extract, Olea Europea L.-related antioxidants, a sodium–glucose cotransporter (SGLT2) inhibitor-rich apple extract and a bergamot polyphenolic fraction, in addition to their support in cardiomyocyte protection, in HF. Such an approach should contribute to optimising the use of nutraceuticals in HF, and the effect needs to be confirmed by means of more targeted clinical trials exploring the efficacy and safety of these compounds.

show abstract

“…Detailed reviews of specific cardiac-enriched (187) and other miRNAs (196) involved in HFrEF and HFpEF (172) are beyond the scope of this article and can be found elsewhere. Using miR-1 as an example, it can be seen that miRNAs are important biological players in the development of HF and are suggested as promising circulating biomarker in HF prognostication, while on the other hand validation of initial findings is pending and methodological issues remain to be solved.…”

Section: Transcriptomics Based Biomarkers-non-coding Rnasmentioning

confidence: 99%

Biomarkers for Heart Failure Prognosis: Proteins, Genetic Scores and Non-coding RNAs

Shrivastava

Haase

Zeller

et al. 2020

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Heart failure (HF) is a complex disease in which cardiomyocyte injury leads to a cascade of inflammatory and fibrosis pathway activation, thereby causing decrease in cardiac function. As a result, several biomolecules are released which can be identified easily in circulating body fluids. The complex biological processes involved in the development and worsening of HF require an early treatment strategy to stop deterioration of cardiac function. Circulating biomarkers provide not only an ideal platform to detect subclinical changes, their clinical application also offers the opportunity to monitor disease treatment. Many of these biomarkers can be quantified with high sensitivity; allowing their clinical application to be evaluated beyond diagnostic purposes as potential tools for HF prognosis. Though the field of biomarkers is dominated by protein molecules, non-coding RNAs (microRNAs, long non-coding RNAs, and circular RNAs) are novel and promising biomarker candidates that encompass several ideal characteristics required in the biomarker field. The application of genetic biomarkers as genetic risk scores in disease prognosis, albeit in its infancy, holds promise to improve disease risk estimation. Despite the multitude of biomarkers that have been available and identified, the majority of novel biomarker candidates are not cardiac-specific, and instead may simply be a readout of systemic inflammation or other pathological processes. Thus, the true value of novel biomarker candidates in HF prognostication remains unclear. In this article, we discuss the current state of application of protein, genetic as well as non-coding RNA biomarkers in HF risk prognosis.

show abstract

miRNAs emerge as circulating biomarkers of post-myocardial infarction heart failure

Cited by 19 publications

References 41 publications

Knockdown of HIF1A‐AS2 suppresses TRIM44 to protect cardiomyocytes against hypoxia‐induced injury

Knockdown of HIF1A‐AS2 suppresses TRIM44 to protect cardiomyocytes against hypoxia‐induced injury

Pathophysiological Basis for Nutraceutical Supplementation in Heart Failure: A Comprehensive Review

Biomarkers for Heart Failure Prognosis: Proteins, Genetic Scores and Non-coding RNAs

Contact Info

Product

Resources

About